The terminal sequences of Bombyx mori 18S ribosomal RNA.

The 5' and 3' terminal T1 oligonucleotides of 32p-labelled B. mori 18S ribosomal RNA were isolated by a two dimensional electrophoretic (diagonal) technique. Nucleotide sequence analysis showed that the 3' terminal fragment, (G)AUCAUUAOH, is identical to that previously obtained from the 18S rRNA of several other eukaryotic species. The sequence of the B. mori 5' terminal fragment is pUCCUCG.     

A new species of Pleistophora (Microsporida: Pleistophoridae) parasitic in the shrimp Palaemonetes pugio

Pleistophora sp. Sprague, 1970, in the muscle of Palaemonetes pugio was studied. Formalin fixed spores were ellipsoidal, 2.5–3.3 × 1.4–2.0 μm, and with large anterior and posterior clear areas representing the polaroplast and posterior vacuole. This species, after comparison with four other species of Pleistophora in decapod crustacea, was found to be new. It is named Pleistophora lintoni n. sp.     

Morphine release and displacement by naloxone in vivo in morphine naive and withdrawn rats

Male Long-Evans rats, implanted in the lateral cerebroventricle with chronic indwelling push-pull cannulae, were perfused (10 μl/min) for 120 min: 20 min with 1.5 × 10^?6M morphine in sterile isotonic saline containing 2.3 mM CaCl₂ (vehicle); 40 min with vehicle; 20 min with 1.5 × 10^?6M morphine; 10 min with vehicle and 30 min with 1 × 10^?6M naloxone in vehicle. These rats and drug-naive rats were implanted s.c. with 2 × 50 mg morphine pellets. After 72 hr the pellets were removed and 18–24 hr later the above perfusion procedure was repeated. The amount of morphine collected in the perfusate during the washout with naloxone was elevated, compared to the amount collected during the corresponding time of the washout with vehicle for both naive and withdrawn groups. The enhanced morphine release during the washout with naloxone did not differ significantly between the naive and withdrawn rats. However, significantly less morphine was recovered in the perfusate collected during the vehicle washout from the withdrawn rats, compared to that collected from the naive rats. The data suggest that $\text{in vivo}$ morphine is specifically bound to receptors and is sensitive to naloxone displacement. It is also concluded that morphine is differentially taken up or otherwise disposed of by brains of rats which are in opiate withdrawal.     

9 alpha-homo-9,11-epoxy-5,13-prostadienoic acid analogues: specific stable agonist (SQ 26, 538) and antagonist (SQ 26, 536) of the human platelet thromboxane receptor

A newly synthesized 9 alpha-homo-9,11-epoxy-5,13-prostadienoic acid analogue, SQ 26, 536, (8(R)9(S)11(R)12(S)-9 alpha-homo-9,11-epoxy-5(Z), 13(E)-15S-hydroxyprostadienoic acid) inhibited arachidonic acid (AA)-induced platelet aggregation with an I50 value of 1.7 microM. SQ 26,536 did not inhibit prostaglandin (PG) synthetase activity of bovine seminal vesicle microsomes or thromboxane (Tx) synthetase activity of lysed human blood platelets. SQ 26,536 also inhibited platelet aggregation induced by epinephrine (secondary phase), 9,11-azoPGH2 and collagen but did not inhibit the primary phase of epinephrine-induced aggregation or ADP-induced platelet aggregation. SQ 26,538 (8(R)9(S)11(R)12(S)-9 alpha-homo-9,11-epoxy-5(Z),13(E)-15R-hydroxyprostadienoic acid), a 15-epimer of SQ 26,536, induced platelet aggregation with an A50 value of 2.5 microM. SQ 26,536 competitively inhibited SQ 26,538-induced platelet aggregation with a Ki value of 3 microM. Neither indomethacin, a PG synthetase inhibitor, nor SQ 80,338 (1-(3-phenyl-2-propenyl)-1H-imidazole), a Tx synthetase inhibitor, inhibited SQ 26,538- or 9,11-azoPGH2-induced platelet aggregation. These data indicate that SQ 26,536 and SQ 26,538 are stable antagonist and agonist, respectively, of the human blood platelet thromboxane receptor.     

A reduced-rank multivariate regression approach to aquatic joint toxicity experiments.

Classical multivariate regression techniques can lead to an asymptotically efficient restricted estimator of the regression matrix if there is evidence that the regression matrix is of reduced rank. A sublethal joint toxicity experiment involving two agents is used to illustrate this approach.     

Induction of the yeast alpha-specific STE3 gene by the peptide pheromone a-factor

The yeast Saccharomyces cerevisiae exhibits two mating types, a and alpha. Efficient mating of a and alpha cells requires the action of peptide pheromones secreted by each cell type. For example, a cells secrete a-factor, which alters the physiology of alpha cells, thereby preparing those cells for mating. To investigate the mechanism by which the pheromones act on the target cells, we have examined the effect of a-factor on expression of the STE3 gene, a gene which is required for mating by alpha cells and which is expressed only in alpha cells. We have monitored STE3 expression by two assays: RNA production from the chromosomal STE3 locus and beta-galactosidase activity produced from a plasmid-borne STE3-lacZ gene fusion. By both assays we show that a-factor induces a rapid increase in STE3 expression. Induction of STE3 RNA occurs even if protein synthesis is blocked by cycloheximide. Using temperature-sensitive cell division cycle mutants, we have also shown that induction occurs in cells arrested at several discrete positions in the cell cycle. These results demonstrate (1) that induction of STE3 expression by a-factor is a primary response to the pheromone, and (2) that alpha cells are capable of responding to a-factor regardless of their position in the cell cycle.